155 related articles for article (PubMed ID: 17027731)
1. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study.
Badri M; Lawn SD; Wood R
Lancet; 2006 Oct; 368(9543):1254-9. PubMed ID: 17027731
[TBL] [Abstract][Full Text] [Related]
2. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
Stringer JS; Zulu I; Levy J; Stringer EM; Mwango A; Chi BH; Mtonga V; Reid S; Cantrell RA; Bulterys M; Saag MS; Marlink RG; Mwinga A; Ellerbrock TV; Sinkala M
JAMA; 2006 Aug; 296(7):782-93. PubMed ID: 16905784
[TBL] [Abstract][Full Text] [Related]
3. [Study on the situation of antiretroviral therapy against HIV/AIDS in Henan province based on the CD4+ T cells count and virus load].
Liu J; Cui WG; Sun GQ; Zhu XP; Tian SA; Sun DY; Yang WJ; Li N; Zhu Q; Wang Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Sep; 31(9):1013-6. PubMed ID: 21162867
[TBL] [Abstract][Full Text] [Related]
4. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
5. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
Lawn SD; Myer L; Bekker LG; Wood R
BMC Infect Dis; 2006 Mar; 6():59. PubMed ID: 16551345
[TBL] [Abstract][Full Text] [Related]
6. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.
Gabillard D; Lewden C; Ndoye I; Moh R; Segeral O; Tonwe-Gold B; Etard JF; Pagnaroat M; Fournier-Nicolle I; Eholié S; Konate I; Minga A; Mpoudi-Ngole E; Koulla-Shiro S; Zannou DM; Anglaret X; Laurent C;
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):555-61. PubMed ID: 23274931
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for mortality in a south Indian population on generic antiretroviral therapy.
Rupali P; Mannam S; Bella A; John L; Rajkumar S; Clarence P; Pulimood SA; Samuel P; Karthik R; Abraham OC; Mathai D
J Assoc Physicians India; 2012 Dec; 60():11-4. PubMed ID: 23781664
[TBL] [Abstract][Full Text] [Related]
8. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
Diabaté S; Alary M
HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
[TBL] [Abstract][Full Text] [Related]
9. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
10. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R;
HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860
[TBL] [Abstract][Full Text] [Related]
12. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
; Lodwick RK; Sabin CA; Porter K; Ledergerber B; van Sighem A; Cozzi-Lepri A; Khaykin P; Mocroft A; Jacobson L; De Wit S; Obel N; Castagna A; Wasmuth JC; Gill J; Klein MB; Gange S; Riera M; Mussini C; Gutiérrez F; Touloumi G; Carrieri P; Guest JL; Brockmeyer NH; Phillips AN
Lancet; 2010 Jul; 376(9738):340-5. PubMed ID: 20638118
[TBL] [Abstract][Full Text] [Related]
13. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
14. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
15. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study.
Lee JS; Humes E; Hogan BC; Justice AC; Klein M; Gebo K; John Gill M; Silverberg MJ; Rebeiro P; Horberg M; Karris M; Rabkin C; Moore RD; Althoff KN;
Lancet HIV; 2022 Mar; 9 Suppl 1():S2. PubMed ID: 35304844
[TBL] [Abstract][Full Text] [Related]
16. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.
Jacobson MA; Zegans M; Pavan PR; O'Donnell JJ; Sattler F; Rao N; Owens S; Pollard R
Lancet; 1997 May; 349(9063):1443-5. PubMed ID: 9164318
[TBL] [Abstract][Full Text] [Related]
18. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
19. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.
Anglaret X; Minga A; Gabillard D; Ouassa T; Messou E; Morris B; Traore M; Coulibaly A; Freedberg KA; Lewden C; Ménan H; Abo Y; Dakoury-Dogbo N; Toure S; Seyler C;
Clin Infect Dis; 2012 Mar; 54(5):714-23. PubMed ID: 22173233
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
